1549 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Lymphatic Diseases" (1549 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting National Lymphatic Disease and Lymphedema Registry
Condition: Lymphedema
Intervention:
2 Unknown  Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder;   Canale-Smith Syndrome
Intervention:
3 Recruiting Sildenafil for the Treatment of Lymphatic Malformations
Conditions: Lymphatic Malformations;   Lymphatic Diseases
Interventions: Drug: Sildenafil 20 mg tablets;   Other: Placebo tablets (resembling Revatio)
4 Recruiting Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Conditions: Lymphatic Diseases;   Hematopoietic Malignancy
Intervention: Biological: Umbilical Cord Blood (UCB)
5 Recruiting Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Conditions: Lymphangiomatosis;   Lymphedema;   Lymphangiectasia;   Pulmonary Lymphangiectasia
Intervention:
6 Unknown  Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Condition: Lymphedema
Intervention: Drug: near-infrared fluorescence imaging
7 Recruiting Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Non-hodgkin Lymphoma or Multiple Myeloma
Conditions: Non-Hodgkin Lymphoma;   Multiple Myeloma
Intervention: Drug: ABT-199
8 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
9 Recruiting Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Radiation: Yttrium Y 90 Ibritumomab tiuxetan;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Biological: Rituximab;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
10 Unknown  TREatment of degeNerative and Neoplastic Diseases With Rituximab
Condition: Diffuse Large B Cell Lymphoma
Intervention: Biological: Rituximab
11 Unknown  Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy
Conditions: Lymphoma;   Kikuchi's Disease
Intervention:
12 Recruiting Bronchoscopic Sampling Techniques in Sarcoidosis
Conditions: Mediastinal Lymph Node Enlargement;   Sarcoidosis;   Tuberculosis;   Lymphomas
Interventions: Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB);   Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA);   Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes;   Procedure: Bronchoalveolar lavage (BAL);   Procedure: Endobronchial forceps biopsy
13 Recruiting Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years
Condition: Acute Lymphoblastic Leukemia Ph Positive
Interventions: Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Vincristine
14 Recruiting Treatment Response to Different Lymphoedema Compression Programs Using a Pneumatic Compression Device
Conditions: Lower Extremity Lymphoedema;   Leg Lymphoedema
Interventions: Device: pneumatic compression 1 hour per day;   Device: pneumatic compression - 2 hours per day;   Device: pneumatic compression - 4 hours per day
15 Recruiting EZN-2279 in Patients With ADA-SCID
Conditions: ADA-SCID;   Adenosine Deaminase Deficiency;   Severe Combined Immunodeficiency
Intervention: Biological: EZN-2279
16 Recruiting PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Conditions: Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Intervention: Drug: TG-0054 combined with G-CSF
17 Unknown  High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
Condition: Lymphoblastic Leukemia, Acute
Interventions: Drug: Cyclophosphamide;   Drug: Daunorubicin;   Drug: Vincristine;   Drug: Prednisolone;   Drug: L-asparaginase;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Mercaptopurine;   Drug: Doxorubicin
18 Recruiting A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Conditions: Interstitial Lung Diseases;   Idiopathic Pulmonary Fibrosis;   Sarcoidosis
Intervention:
19 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Conditions: Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
Intervention:
20 Recruiting Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).
Condition: Mantle Cell Lymphoma Refractory
Interventions: Drug: Torisel dose 15 mg and R-CHOP;   Drug: Torisel dose 15 mg and R-FC;   Drug: Torisel dose 15 mg and R-DHA;   Drug: Torisel dose 25 mg and R-CHOP;   Drug: Torisel dose 50 mg and R-CHOP;   Drug: Torisel dose 75 mg and R-CHOP;   Drug: Torisel dose 25 mg and R-FC;   Drug: Torisel dose 50 mg and R-FC;   Drug: Torisel dose 75 mg and R-FC;   Drug: Torisel dose 25 mg and R-DHA;   Drug: Torisel dose 50 mg and R-DHA;   Drug: Torisel 75 mg and R-DHA

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years